Case Report : Diagnosis and Management of Peripartum Cardiomyopathy
Main Article Content
Abstract
Introduction: Peripartum cardiomyopathy (PPCM) is generally viewed as diagnosis of exclusion in women presenting with heart failure and systolic dysfunction of unclear identifiable etiology. Etiology of PPCM is not fully understood and multifactorial. The purpose of this case is to review the diagnosis and management PPCM based on our experience in managing 31 years old woman with PPCM.
Case: A 31 year old woman presented with dyspnea persisting for two days, exacerbated over the last 24 hours. She gave birth to her third child seven months ago. Patient had been experiencing dyspnea since 4 months earlier but seek no medical help. Upon physical examination, hemodynamic was stable, wet rales was noted in two thirds of the lung fields. Echocardiography revealed dilated left ventricle with eccentric hypertrophy and reduced ejection fraction (18%). Treatment was initiated with furosemide IV to resolve dyspnea, then Ramipril, bisoprolol, forxiga and spironolactone was given as heart failure therapy.
Discussion: PPCM should be suspected in any peripartum women presenting with symptoms and signs of heart failure. Careful history taking and diagnostic testing especially echocardiography is important to help physicians determine the diagnosis.
Conclusion: Treatment with medication adjusted for pregnancy and lactation may prevent adverse outcome, improve clinical symptoms and improve the overall cardiac functions. Long term follow up is important for patients with PPCM, since the optimal duration of medications after recovery is still unknown.
Downloads
Article Details
Copyright (c) 2023 Sidhi Laksono, Veronica Nadya Puteri Nandifa
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Cooney, R., Scott, J. R., Mahowald, M., Langen, E., Sharma, G., Kao, D. P., & Davis, M. B. (2022). Heart rate as an early predictor of severe cardiomyopathy and increased mortality in peripartum cardiomyopathy. Clinical Cardiology, 45(2), 205–213. https://doi.org/10.1002/clc.23782 DOI: https://doi.org/10.1002/clc.23782
Davis, M. B., Arany, Z., McNamara, D. M., Goland, S., & Elkayam, U. (2020). Peripartum Cardiomyopathy: JACC State of the art Review. Journal of the American College of Cardiology, 75(2), 207–221. https://doi.org/10.1016/j.jacc.2019.11.014 DOI: https://doi.org/10.1016/j.jacc.2019.11.014
DeSa, T., & Gong, T. (2021). SGLT2 inhibitors: a new pillar of the heart failure regimen. Reviews in Cardiovascular Medicine, 22(4), 1253. https://doi.org/10.31083/j.rcm2204133 DOI: https://doi.org/10.31083/j.rcm2204133
Hilfiker-Kleiner, D., Struman, I., Hoch, M., Podewski, E., & Sliwa, K. (2012). 16-kDa Prolactin and Bromocriptine in Postpartum Cardiomyopathy. Current Heart Failure Reports, 9(3), 174–182. https://doi.org/10.1007/s11897-012-0095-7 DOI: https://doi.org/10.1007/s11897-012-0095-7
Hoevelmann, J., Viljoen, C. A., Manning, K., Baard, J., Hahnle, L., Ntsekhe, M., Bauersachs, J., & Sliwa, K. (2019). The prognostic significance of the 12-lead ECG in peripartum cardiomyopathy. International Journal of Cardiology, 276, 177–184. https://doi.org/10.1016/j.ijcard.2018.11.008 DOI: https://doi.org/10.1016/j.ijcard.2018.11.008
Honigberg, M. C., & Givertz, M. M. (2019). Peripartum Cardiomyopathy. BMJ, k5287. https://doi.org/10.1136/bmj.k5287 DOI: https://doi.org/10.1136/bmj.k5287
Iorgoveanu, C., Zaghloul, A., & Ashwath, M. (2021). Peripartum cardiomyopathy: a review. Heart Failure Reviews, 26(6), 1287–1296. https://doi.org/10.1007/s10741-020-10061-x DOI: https://doi.org/10.1007/s10741-020-10061-x
Kearney, L., Wright, P., Fhadil, S., & Thomas, M. (2018). Postpartum Cardiomyopathy and Considerations for Breastfeeding. Cardiac Failure Review, 4(2), 112. https://doi.org/10.15420/cfr.2018.21.2 DOI: https://doi.org/10.15420/cfr.2018.21.2
Laksono, S., Prawara, A. S., & Halomoan, R. (2021). Diagnosis and Management of Severe Peripartum Cardiomyopathy. Indonesian Journal of Obstetrics and Gynecology, 215–218. https://doi.org/10.32771/inajog.v9i4.1459 DOI: https://doi.org/10.32771/inajog.v9i4.1459
Lam, C. S. P., Chandramouli, C., Ahooja, V., & Verma, S. (2019). SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. Journal of the American Heart Association, 8(20). https://doi.org/10.1161/JAHA.119.013389 DOI: https://doi.org/10.1161/JAHA.119.013389
Sliwa, K., Bauersachs, J., Arany, Z., Spracklen, T. F., & Hilfiker-Kleiner, D. (2021). Peripartum cardiomyopathy: from genetics to management. European Heart Journal, 42(32), 3094–3102. https://doi.org/10.1093/eurheartj/ehab458 DOI: https://doi.org/10.1093/eurheartj/ehab458
Ziccardi, M. R., & Siddique, M. S. (2023). Peripartum Cardiomyopathy. In StatPearls [Internet]. StatPearls Publishing.